SPIN1 is identified as a novel target of the miR-148/152 family and enhances Adriamycin resistance by regulating drug metabolizing enzymes and transporter CYP2C8, UGT2B4, UGT2B17 and ABCB4 in breast cancer (Fig. 5i). Here, UGT2B4 is linked to breast carcinoma.